Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

List today: American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Kahn serves as an advisory panel member/consultant for Abarceo Pharma, Amgen, AltPep, Anji, Biomea Fusion, Eli Lilly and Company, Merck, Neurimmune, Novo Nordisk, and Oramed and receives research ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

Corcept Therapeutics announced Wednesday that its experimental treatment for Cushing’s syndrome missed the primary endpoint ...